JP2021527059A - 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断 - Google Patents

置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断 Download PDF

Info

Publication number
JP2021527059A
JP2021527059A JP2020567947A JP2020567947A JP2021527059A JP 2021527059 A JP2021527059 A JP 2021527059A JP 2020567947 A JP2020567947 A JP 2020567947A JP 2020567947 A JP2020567947 A JP 2020567947A JP 2021527059 A JP2021527059 A JP 2021527059A
Authority
JP
Japan
Prior art keywords
cancer
optionally substituted
alkyl
cell
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020567947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527059A5 (enExample
Inventor
マシュー、コストゥラ
マイケル、ルーサー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bantam Pharmaceutical LLC
Original Assignee
Bantam Pharmaceutical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical LLC filed Critical Bantam Pharmaceutical LLC
Publication of JP2021527059A publication Critical patent/JP2021527059A/ja
Publication of JP2021527059A5 publication Critical patent/JP2021527059A5/ja
Priority to JP2024172786A priority Critical patent/JP2025016393A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020567947A 2018-06-07 2019-06-07 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断 Ceased JP2021527059A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024172786A JP2025016393A (ja) 2018-06-07 2024-10-01 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682132P 2018-06-07 2018-06-07
US62/682,132 2018-06-07
PCT/US2019/035992 WO2019236966A2 (en) 2018-06-07 2019-06-07 Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024172786A Division JP2025016393A (ja) 2018-06-07 2024-10-01 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断

Publications (2)

Publication Number Publication Date
JP2021527059A true JP2021527059A (ja) 2021-10-11
JP2021527059A5 JP2021527059A5 (enExample) 2023-12-21

Family

ID=67003746

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567947A Ceased JP2021527059A (ja) 2018-06-07 2019-06-07 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断
JP2024172786A Pending JP2025016393A (ja) 2018-06-07 2024-10-01 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024172786A Pending JP2025016393A (ja) 2018-06-07 2024-10-01 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断

Country Status (7)

Country Link
US (1) US20210278408A1 (enExample)
EP (1) EP3801770A2 (enExample)
JP (2) JP2021527059A (enExample)
CN (1) CN112770813A (enExample)
BR (1) BR112020024794A2 (enExample)
IL (1) IL279212A (enExample)
WO (1) WO2019236966A2 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196644A1 (en) * 2015-06-01 2016-12-08 Bantam Pharmaceutical, Llc Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056907B (zh) * 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
CN105208578A (zh) 2014-06-24 2015-12-30 中兴通讯股份有限公司 一种基站优化方法及装置
JP6090520B1 (ja) 2016-07-14 2017-03-08 東洋インキＳｃホールディングス株式会社 ラミネート用グラビアインキ組成物、印刷物、および積層体
KR101807044B1 (ko) 2016-10-12 2017-12-08 현대자동차 주식회사 Cda 장치 및 물 펌프가 장착된 엔진 및 이를 제어하는 방법
MX2019006299A (es) * 2016-11-30 2019-11-12 Bantam Pharmaceutical Llc Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
CN107177673A (zh) * 2017-06-02 2017-09-19 北京泱深生物信息技术有限公司 腹动脉瘤诊治相关基因

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196644A1 (en) * 2015-06-01 2016-12-08 Bantam Pharmaceutical, Llc Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 27(18), JPN6023023906, 2017, pages 4471 - 4477, ISSN: 0005080546 *
CELL DEATH & DISEASE, vol. 8(6), JPN6023023905, 2017, pages 2870, ISSN: 0005080547 *

Also Published As

Publication number Publication date
JP2025016393A (ja) 2025-01-31
WO2019236966A3 (en) 2020-02-13
IL279212A (en) 2021-01-31
EP3801770A2 (en) 2021-04-14
US20210278408A1 (en) 2021-09-09
WO2019236966A2 (en) 2019-12-12
BR112020024794A2 (pt) 2021-03-02
CN112770813A (zh) 2021-05-07

Similar Documents

Publication Publication Date Title
CN110003204B (zh) 一种bet蛋白抑制剂、其制备方法及用途
AU2014337300B2 (en) Hydrochloride salt form for EZH2 inhibition
JP5670266B2 (ja) フラザノベンゾイミダゾール
US7491829B2 (en) RAF inhibitor compounds and methods
JP7373992B2 (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
JPWO2008001886A1 (ja) オーロラ（Ａｕｒｏｒａ）阻害剤
JP2025000782A (ja) エストロゲン受容体アンタゴニストのレジメン
JP2020105195A (ja) Ｒａｌ ＧＴＰアーゼを標的とする抗癌化合物及びそれを使用する方法
WO2011137587A1 (en) Cytokine inhibitors
TW201422616A (zh) 作爲Ｓｙｋ抑制劑的取代吡啶並吡嗪類化合物
Liu et al. Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity
CN108473472A (zh) 作为p70s6激酶抑制剂的2-氨基喹唑啉衍生物
CN115974855A (zh) Ezh2和hdac双靶点抑制剂、其药物组合物及其制备方法和用途
JP2019526617A (ja) 治療用化合物
JP2025016393A (ja) 置換ピロール及びピラゾール化合物による癌の治療方法、並びに、置換ピロール及びピラゾール化合物による治療に影響を受けやすい癌の診断
CN113891749A (zh) 喹啉衍生物及其用于治疗癌症的用途
CA3107750A1 (en) Cdk inhibitors and uses thereof
AU2013328979A1 (en) Compounds for treating Rac-GTPase mediated disorder
CN115819349B (zh) 一种吡唑类化合物及其制备方法和应用
TW202034911A (zh) 肥胖症的治療
US20250109120A1 (en) Indoline derivatives for treatment and/or prevention of tumor or cell proliferative and fibrosis diseases
TWI895316B (zh) 以縮合嘧啶化合物作為有效成分之治療劑
CN107849033A (zh) 用于治疗Rac‑GTP酶介导的病症的化合物
HK40088938A (en) Kat6 inhibitor methods and combinations for cancer treatment
US20250235453A1 (en) Triazolopyridazine compounds useful as rac1 inhibitors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231109

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20231211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240716

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240902

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20241220